Cohen Klingenstein’s Nu Skin NUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-4,200
Closed -$238K 247
2021
Q2
$238K Hold
4,200
0.01% 237
2021
Q1
$222K Hold
4,200
0.01% 237
2020
Q4
$229K Hold
4,200
0.01% 232
2020
Q3
$210K Buy
+4,200
New +$199K 0.01% 228
2019
Q3
Sell
-4,200
Closed -$207K 240
2019
Q2
$207K Hold
4,200
0.01% 208
2019
Q1
$201K Hold
4,200
0.01% 191
2018
Q4
$258K Hold
4,200
0.04% 151
2018
Q3
$346K Hold
4,200
0.04% 148
2018
Q2
$328K Hold
4,200
0.04% 150
2018
Q1
$310K Hold
4,200
0.04% 149
2017
Q4
$287K Hold
4,200
0.04% 153
2017
Q3
$258K Hold
4,200
0.04% 153
2017
Q2
$264K Hold
4,200
0.04% 153
2017
Q1
$233K Hold
4,200
0.04% 156
2016
Q4
$201K Hold
4,200
0.03% 157
2016
Q3
$272K Buy
+4,200
New +$236K 0.05% 149
2015
Q3
Sell
-4,515
Closed -$213K 157
2015
Q2
$213K Hold
4,515
0.04% 155
2015
Q1
$272K Buy
+4,515
New +$230K 0.05% 148
2014
Q4
Sell
-6,849
Closed -$308K 159
2014
Q3
$308K Hold
6,849
0.05% 143
2014
Q2
$507K Hold
6,849
0.1% 123
2014
Q1
$567K Sell
6,849
-187
-3% -$16.4K 0.11% 112
2013
Q4
$973K Sell
7,036
-420
-6% -$49.5K 0.19% 85
2013
Q3
$714K Hold
7,456
0.16% 95
2013
Q2
$456K Buy
+7,456
New +$414K 0.11% 118

Other funds holding NUS

Cohen Klingenstein's NUS Position: Q3 2021 in Review

Cohen Klingenstein sold out of Nu Skin (NUS) in Q3 2021, closing a stake of 4,200 shares — an estimated $238K sold.

Cohen Klingenstein first reported a position in NUS in Q2 2013 and held it in 24 quarters. The position peaked at $973K in Q4 2013. 246 funds tracked by Wall St. Rank hold NUS as of Q3 2021.

  • Cohen Klingenstein reported no remaining Nu Skin position as of Q3 2021 after selling out during the quarter.
  • Cohen Klingenstein sold 4,200 Nu Skin shares in Q3 2021, an estimated $238K.
  • Cohen Klingenstein first reported a position in Nu Skin in Q2 2013 and held it in 24 quarters.
  • Cohen Klingenstein's Nu Skin position peaked at $973K in Q4 2013.
  • 246 funds tracked by Wall St. Rank held Nu Skin as of Q3 2021.

Based on Cohen Klingenstein's 13F filing for Q3 2021, filed 15 Oct 2021.